Get App

BridgeBio Pharma's heart disease drug meets main goal in late-stage study

The company said no safety concerns were identified in patients, adding that it intends to submit marketing applications to the US Food and Drug Administration before the end of 2023, with regulatory filings in additional markets to follow in 2024.
  • Updated On Jul 17, 2023 at 05:49 PM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
Bengaluru: BridgeBio Pharma Inc said on Monday its experimental drug to treat a kind of heart disease showed statistically significant improvement in reducing hospitalizations in a late-stage study, sending shares up 64per cent.

The company said no safety concerns were identified in patients, adding that it intends to submit marketing applications to the US Food and Drug Administration before the end of 2023, with regulatory filings in additional markets to follow in 2024.

The drug, acoramidis, is being developed to treat a rare disease that can lead to heart failure, the company said.
  • Published On Jul 17, 2023 at 05:40 PM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App